Search
Results: 11
Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes
This work was supported by the Wellcome Trust Translational Medicine and Therapeutics Programme [RJAG/076 to TJ], Cancer Research UK and the Cambridge Translational Medicine and Therapeutics Academic Clinical Fellowship...
Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
Geoffrey S Williams, Bina Mistry, Sandrine Guillard, Jane Coates Ulrichsen, Alan M Sandercock, Jun Wang, Andrea González-Muñoz, Julie Parmentier, Chelsea Black, Jo Soden, Jim Freeth, Jelena Jovanović, Rebecca Leyland, Rafia S Al-Lamki, Andrew J Leishman, Steven J Rust, Ross Stewart, Lutz Jermutus, John R Bradley, Vahe Bedian, Viia Valge-Archer, Ralph Minter, Robert W Wilkinson
Jul 20, 2018
TNFR2 cancer immunotherapy Drug Discovery phenotypic screening Regulatory T cell Animals Antineoplastic Agents Cell Line Tumor Drug Screening Assays Antitumor Female HEK293 Cells Humans Immunotherapy Jurkat Cells Mice Inbred BALB C NF-kappa B Neoplasms Neoplasms Experimental Phenotype Receptors Tumor Necrosis Factor Type II Signal Transduction T-Lymphocytes Regulatory
Selective inhibition of mTORC1 in tumor vessels increases antitumor immunity.
Shan Wang, Ariel Raybuck, Eileen Shiuan, Sung Hoon Cho, Qingfei Wang, Dana M Brantley-Sieders, Deanna Edwards, Margaret M Allaman, James Nathan, Keith T Wilson, David DeNardo, Siyuan Zhang, Rebecca Cook, Mark Boothby, Jin Chen
Aug 18, 2020
A tumor blood vessel is a key regulator of tissue perfusion, immune cell trafficking, cancer metastasis, and therapeutic responsiveness. mTORC1 is a signaling node downstream of multiple angiogenic factors in the endothelium....
Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
Ee Lyn Lim, Fiorella M Cugliandolo, Dalya R Rosner, David Gyori, Rahul Roychoudhuri, Klaus Okkenhaug
Aug 20, 2018
Adaptive Immunity cancer immunotherapy immunology oncology Signal Transduction Animals Antigens Neoplasm Antineoplastic Agents Immunological Antineoplastic Combined Chemotherapy Protocols Cancer vaccines Cell Line Tumor Class I Phosphatidylinositol 3-Kinases Costimulatory and Inhibitory T-Cell Receptors Diphtheria Toxin Disease Models Animal Drug Interactions Female Humans Lymphocyte Depletion Male Mice Neoplasms Phosphatidylinositol 3-Kinases Phosphoinositide-3 Kinase Inhibitors Purines Quinazolinones Signal Transduction T-Lymphocytes Cytotoxic T-Lymphocytes Regulatory Treatment Outcome
NKG2A Immune Checkpoint in Vδ2 T Cells
Valentina Cazzetta, Delphine Depierreux, Francesco Colucci, Joanna Mikulak, Domenico Mavilio
Mar 28, 2023
Immune regulation has revolutionized cancer treatment with the introduction of T-cell-targeted immune checkpoint inhibitors (ICIs). This successful immunotherapy has led to a more complete view of cancer that now considers not...
NKG2A inhibitory receptors cancer immunotherapy γδ T cells Therapeutic monoclonal antibodies Immune Checkpoint Inhibitors
Published by: Cancers
Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
David Gyori, Ee Lyn Lim, Francis M Grant, Dominik Spensberger, Rahul Roychoudhuri, Stephen J Shuttleworth, Klaus Okkenhaug, Len R Stephens, Phillip T Hawkins
Aug 20, 2018
cancer immunotherapy immunology MACROPHAGES oncology T cells Aminopyridines Animals Cell Line Tumor Class I Phosphatidylinositol 3-Kinases Diphtheria Toxin Disease Models Animal Drug Resistance Neoplasm Female Forkhead Transcription Factors Gene Knockout Techniques Humans Lymphocyte Depletion MACROPHAGES Male Mice Mice Transgenic Neoplasms Phosphatidylinositol 3-Kinases Phosphoinositide-3 Kinase Inhibitors Primary Cell Culture Purines Pyrroles Quinazolinones Receptors Granulocyte-Macrophage Colony-Stimulating Factor T-Lymphocytes Regulatory Tumor Microenvironment
Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity
TR Flint, T Janowitz, CM Connell, EW Roberts, AE Denton, AP Coll, DI Jodrell, DT Fearon
Dec 20, 2016
Sustained expansion of NKT cells and antigen-specific T cells after injection of ?-galactosyl-ceramide loaded mature dendritic cells in cancer patients
Natural killer T (NKT) cells are distinct glycolipid reactive innate lymphocytes that are implicated in the resistance to pathogens and tumors. Earlier attempts to mobilize NKT cells, specifically, in vivo in humans met with...
utoimmune disease cancer immunotherapy cytokine production Cytomegalovirus cytotoxic T lymphocyte dendritic cell natural killer cell Vaccination
Published by: Rockefeller University